The FDA on October 1, 2021, approved TECARTUS® (Brexucabtagene autoleucel) for adult patients with Relapsed or Refractory B-cell precursor Acute Lymphoblastic Leukemia (ALL). TECARTUS® is a product of Kite Pharma, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
